MedTrace Logo

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

NCT05349019 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2023-01-18

No results posted yet for this study

Summary

To characterize using a participant centered decentralized (at home) study featuring wearable technology and telemedicine to study disease change over time in patients with PD caused by the G2019S mutation in the LRRK2 gene and to identify a clinical endpoint(s) for disease modifying experimental therapy trials.

Conditions

  • Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene

Interventions

OTHER

Observational

This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.

Sponsors & Collaborators

  • Momentum Pharma

    collaborator INDUSTRY

  • Science 37

    collaborator INDUSTRY

  • Escape Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Carrolee Barlow, MD, PhD · Escape Bio, Inc.

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-02
Primary Completion
2022-08-05
Completion
2022-08-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05349019 on ClinicalTrials.gov